Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2022-12-19 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
江苏四环生物股份有限公司关于拟为控股子公司申请银行授信额度提供担保的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the company's decision to provide a guarantee for a bank credit facility applied for by its controlling subsidiary. It includes details about the guarantee, the subsidiary's financial data, and board opinions on the matter. There is no indication that this is a full financial report, audit report, or earnings release. It is a specific corporate announcement about financing-related guarantees. This fits best under the category of Capital/Financing Update (CAP), as it relates to updates on financing activities and guarantees provided by the company.
2022-12-19 Chinese
江苏四环生物股份有限公司第九届董事会第十六次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the company's board of directors regarding a decision made at a board meeting. It includes details about the meeting attendance, the agenda item (approval of guarantee for a subsidiary's bank credit application), and the voting results. There is no financial data, no mention of annual or quarterly reports, no audit information, and no shareholder voting results at a general meeting. The content fits the category of Board/Management Information, as it announces decisions made by the board of directors.
2022-12-19 Chinese
2022年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '江苏四环生物股份有限公司2022 年第三季度报告' which translates to 'Jiangsu Sihuan Biological Co., Ltd. 2022 Third Quarter Report'. It contains detailed financial data including income statement, balance sheet, cash flow statement, and notes on financial metrics for the third quarter of 2022. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. It also mentions that the report is unaudited. The length of the document (over 12,000 characters) and the presence of detailed financial data confirm it is the actual interim/quarterly report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-25 Chinese
江苏四环生物股份有限公司关于诉讼的进展公告
Legal Proceedings Report Classification · 95% confidence The document is an announcement regarding the progress of litigation involving the company 江苏四环生物股份有限公司. It details the parties involved, the nature of the lawsuits (securities false statement liability disputes), the claims for damages, and recent developments including changes in litigation requests based on new judicial interpretations. There is no financial data, earnings, or report attached or referenced as being published. The document is a legal proceeding update informing investors about ongoing lawsuits and their potential impact on the company. Therefore, it fits the category of Legal Proceedings Report (LTR). The document length is 2167 characters, which is consistent with an announcement rather than a full report.
2022-09-23 Chinese
四环生物2022年第二次临时股东大会法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter from a law firm regarding the legality and validity of the convening, attendance, voting procedures, and results of the 2022 second extraordinary general meeting of shareholders of Jiangsu Sihuan Bioengineering Co., Ltd. It details the compliance with relevant laws, regulations, and company articles, and confirms the legitimacy of the meeting and its resolutions. This is not a report of the meeting itself, nor an announcement of voting results, but a legal opinion on the meeting's procedures and outcomes. Such legal opinion letters related to shareholder meetings are typically classified under Regulatory Filings (RNS) as they do not fit into other specific categories like Declaration of Voting Results (DVA) or AGM Information (AGM-R). The document length is short (2431 characters) and it is a standalone legal opinion, not a full report or announcement of results.
2022-09-06 Chinese
江苏四环生物股份有限公司2022年第二次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled as a resolution announcement for the 2022 second extraordinary general meeting of shareholders of Jiangsu Sihuan Bio. It details the meeting date, attendance, voting results on proposals, and includes a legal opinion on the validity of the meeting and resolutions. There is no financial data or detailed report content, only the official announcement of voting results and meeting outcomes. This fits the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA). The document length is short and focused on voting results, not a full report or presentation.
2022-09-06 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.